Which has better earnings & valuation, COGT or BCAX?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is COGT or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Bicara Therapeutics N/A -35.89% -33.78%

Does the media refer more to COGT or BCAX?

In the previous week, Cogent Biosciences and Cogent Biosciences both had 4 articles in the media. Cogent Biosciences' average media sentiment score of 1.73 beat Bicara Therapeutics' score of 0.17 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bicara Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BCAX or MIRM?

In the previous week, Mirum Pharmaceuticals had 31 more articles in the media than Bicara Therapeutics. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.17 beat Mirum Pharmaceuticals' score of 0.11 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor BCAX or CGON?

In the previous week, CG Oncology had 25 more articles in the media than Bicara Therapeutics. MarketBeat recorded 29 mentions for CG Oncology and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.17 beat CG Oncology's score of 0.03 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Is BCAX or XENE more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -35.89% -33.78% Xenon Pharmaceuticals N/A -43.98% -41.72%

Does the media refer more to BCAX or XENE?

In the previous week, Xenon Pharmaceuticals had 11 more articles in the media than Bicara Therapeutics. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 4 mentions for Bicara Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Bicara Therapeutics' score of 0.17 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LGND or BCAX?

In the previous week, Ligand Pharmaceuticals had 25 more articles in the media than Bicara Therapeutics. MarketBeat recorded 29 mentions for Ligand Pharmaceuticals and 4 mentions for Bicara Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.57 beat Bicara Therapeutics' score of 0.17 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bicara Therapeutics (BCAX) Competitors

$28.15 +0.09 (+0.32%)

As of 10:28 AM Eastern

Compare

BCAX vs. COGT, MIRM, CGON, XENE, and LGND

Should you buy Bicara Therapeutics stock or one of its competitors? MarketBeat compares Bicara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicara Therapeutics include Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), Xenon Pharmaceuticals (XENE), and Ligand Pharmaceuticals (LGND). These companies are all part of the "biotechnology" industry.

How does Bicara Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Cogent Biosciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Cogent Biosciences currently has a consensus price target of $45.90, indicating a potential upside of 11.53%. Bicara Therapeutics has a consensus price target of $30.27, indicating a potential upside of 7.54%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Cogent Biosciences is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Cogent Biosciences and Cogent Biosciences both had 4 articles in the media. Cogent Biosciences' average media sentiment score of 1.73 beat Bicara Therapeutics' score of 0.17 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bicara Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cogent Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, meaning that its stock price is 175% less volatile than the broader market.

Bicara Therapeutics' return on equity of -35.89% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Summary

Cogent Biosciences beats Bicara Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Bicara Therapeutics compare to Mirum Pharmaceuticals?

Bicara Therapeutics (NASDAQ:BCAX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Bicara Therapeutics currently has a consensus target price of $30.27, indicating a potential upside of 7.54%. Mirum Pharmaceuticals has a consensus target price of $137.33, indicating a potential upside of 39.02%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Bicara Therapeutics has a beta of -0.75, suggesting that its share price is 175% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 31 more articles in the media than Bicara Therapeutics. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.17 beat Mirum Pharmaceuticals' score of 0.11 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Bicara Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Bicara Therapeutics' return on equity of -35.89% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Mirum Pharmaceuticals has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Mirum Pharmaceuticals	$521.31M	12.30	-$23.36M	-$14.55	N/A

Summary

Mirum Pharmaceuticals beats Bicara Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Bicara Therapeutics compare to CG Oncology?

Bicara Therapeutics (NASDAQ:BCAX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Bicara Therapeutics has higher earnings, but lower revenue than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
CG Oncology	$4.04M	1,641.92	-$160.99M	-$2.69	N/A

Bicara Therapeutics has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -26.58% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
CG Oncology	-3,602.68%	-26.58%	-25.34%

Bicara Therapeutics presently has a consensus target price of $30.27, suggesting a potential upside of 7.54%. CG Oncology has a consensus target price of $83.18, suggesting a potential upside of 11.15%. Given CG Oncology's higher probable upside, analysts plainly believe CG Oncology is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

26.6% of CG Oncology shares are owned by institutional investors. 13.8% of Bicara Therapeutics shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bicara Therapeutics has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

In the previous week, CG Oncology had 25 more articles in the media than Bicara Therapeutics. MarketBeat recorded 29 mentions for CG Oncology and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.17 beat CG Oncology's score of 0.03 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

CG Oncology beats Bicara Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Bicara Therapeutics compare to Xenon Pharmaceuticals?

Bicara Therapeutics (NASDAQ:BCAX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Xenon Pharmaceuticals had 11 more articles in the media than Bicara Therapeutics. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 4 mentions for Bicara Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Bicara Therapeutics' score of 0.17 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Bicara Therapeutics has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Xenon Pharmaceuticals	$7.50M	815.44	-$345.91M	-$4.74	N/A

Bicara Therapeutics' return on equity of -35.89% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Bicara Therapeutics presently has a consensus price target of $30.27, indicating a potential upside of 7.54%. Xenon Pharmaceuticals has a consensus price target of $77.13, indicating a potential upside of 21.92%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Xenon Pharmaceuticals beats Bicara Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Bicara Therapeutics compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Ligand Pharmaceuticals has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$290.54M	20.06	$124.45M	$9.35	31.10
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

In the previous week, Ligand Pharmaceuticals had 25 more articles in the media than Bicara Therapeutics. MarketBeat recorded 29 mentions for Ligand Pharmaceuticals and 4 mentions for Bicara Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.57 beat Bicara Therapeutics' score of 0.17 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Bicara Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Ligand Pharmaceuticals currently has a consensus price target of $336.57, indicating a potential upside of 15.76%. Bicara Therapeutics has a consensus price target of $30.27, indicating a potential upside of 7.54%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Ligand Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Ligand Pharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market.

Summary

Ligand Pharmaceuticals beats Bicara Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAX vs. The Competition

Export

Metric	Bicara Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.84B	$3.71B	$7.02B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-10.08	9.07	269.90	24.97
Price / Sales	N/A	1,294.66	659.13	107.89
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	3.84	17.71	11.29	6.44
Net Income	-$137.95M	-$13.25M	$3.45B	$347.50M
7 Day Performance	9.36%	5.42%	3.56%	3.82%
1 Month Performance	-2.63%	-1.71%	-0.57%	-0.37%
1 Year Performance	175.98%	61.70%	77.67%	23.81%

Bicara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAX Bicara Therapeutics	1.343 of 5 stars	$28.15 +0.3%	$30.27 +7.5%	+175.1%	$1.84B	N/A	N/A	32	Upcoming Earnings
COGT Cogent Biosciences	1.6426 of 5 stars	$42.84 +10.2%	$45.90 +7.1%	+286.8%	$6.64B	N/A	N/A	80	Positive News Earnings Report Gap Down High Trading Volume
MIRM Mirum Pharmaceuticals	2.9712 of 5 stars	$104.33 -0.2%	$143.40 +37.4%	+67.8%	$6.38B	$521.31M	N/A	140	Positive News Earnings Report Analyst Upgrade Analyst Revision
CGON CG Oncology	2.2035 of 5 stars	$71.40 +3.3%	$81.73 +14.5%	+202.2%	$6.10B	$4.04M	N/A	61	Earnings Report Analyst Forecast Analyst Revision
XENE Xenon Pharmaceuticals	2.7364 of 5 stars	$64.01 +2.8%	$77.20 +20.6%	+89.5%	$6.02B	$7.50M	N/A	210	Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicara Therapeutics (BCAX) Competitors

BCAX vs. COGT, MIRM, CGON, XENE, and LGND

How does Bicara Therapeutics compare to Cogent Biosciences?

Summary

How does Bicara Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Bicara Therapeutics compare to CG Oncology?

Summary

How does Bicara Therapeutics compare to Xenon Pharmaceuticals?

Summary

How does Bicara Therapeutics compare to Ligand Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicara Therapeutics (BCAX) Competitors

BCAX vs. COGT, MIRM, CGON, XENE, and LGND

How does Bicara Therapeutics compare to Cogent Biosciences?

Which has better earnings & valuation, COGT or BCAX?

Do analysts recommend COGT or BCAX?

Does the media refer more to COGT or BCAX?

Which has more risk & volatility, COGT or BCAX?

Is COGT or BCAX more profitable?

Summary

How does Bicara Therapeutics compare to Mirum Pharmaceuticals?

Do analysts prefer BCAX or MIRM?

Which has more risk and volatility, BCAX or MIRM?

Does the media prefer BCAX or MIRM?

Is BCAX or MIRM more profitable?

Which has higher valuation and earnings, BCAX or MIRM?

Summary

How does Bicara Therapeutics compare to CG Oncology?

Which has higher earnings & valuation, BCAX or CGON?

Is BCAX or CGON more profitable?

Do analysts rate BCAX or CGON?

Do insiders and institutionals hold more shares of BCAX or CGON?

Which has more risk & volatility, BCAX or CGON?

Does the media favor BCAX or CGON?

Summary

How does Bicara Therapeutics compare to Xenon Pharmaceuticals?

Do institutionals and insiders believe in BCAX or XENE?

Does the media refer more to BCAX or XENE?

Which has more volatility and risk, BCAX or XENE?

Which has better valuation & earnings, BCAX or XENE?

Is BCAX or XENE more profitable?

Do analysts rate BCAX or XENE?

Summary

How does Bicara Therapeutics compare to Ligand Pharmaceuticals?

Which has preferable valuation and earnings, LGND or BCAX?

Does the media prefer LGND or BCAX?

Do insiders & institutionals hold more shares of LGND or BCAX?

Is LGND or BCAX more profitable?

Do analysts prefer LGND or BCAX?

Which has more volatility and risk, LGND or BCAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools